Enteric infections are still extremely common in all parts of the world. They are caused by different viruses, bacteria, parasites and even fungi and symptoms such as diarrhoea can also be associated with toxin ingestion. Although common globally, enteric infections associated with individual pathogens differ dramatically in their geographical distribution and epidemiology. In industrialised countries, enteric infections are normally relatively infrequent on an individual basis, are usually non-life threatening and are sporadic (or occur in small outbreaks). In non-industrialised countries, individuals are often chronically infected (for example with helminths) and may suffer simultaneously from infection by more than one infectious agent. In addition, in the poorer nations of the world, enteric infections are responsible for a great deal of chronic morbidity and mortality that can be regarded as life threatening. This general description of the current state of affairs has consequences for enteric vaccine development. The key drivers for vaccine development are often economic considerations and, consequently, the development of vaccines to target rare disease in industrialised countries is often neglected. For example, we have made very little progress in vaccine development for eukaryotic pathogens. The problem of effective vaccine development is compounded by the site associated with the initial phases of the establishment of the infection, the intestine. The induction of predominantly systemic immune responses by classical parenteral injection methods may not be the optimal way to induce immunity to a pathogen colonising the intestine.
The induction of specific gut-associated mucosal responses may favour more effective protection. This presents a dilemma to vaccine developers, who often have two options for vaccine development. One involves optimising classical parenteral vaccines delivered by injection. The other involves the development of vaccines that can be delivered directly to mucosal surfaces 1 . The second option usually involves a vaccine formulation suitable for oral delivery. The oral delivery route presents significant demands on a vaccine. Most antigens are poorly immunogenic when delivered mucosally. This is due to a combination of factors including antigen dilution or denaturation and tight immune regulation at mucosal surfaces 2 . Mucosal immune regulation is designed to prevent inadvertent immune responses to dietary or environmental antigens while favouring active immunity to dangerous antigens from pathogens 3 . As we still know relatively little about how this discrimination process works, we cannot easily create highly immunogenic mucosal vaccines from pure, non-living antigens. Therefore, historically, live vaccines have been favoured for oral vaccine development, although novel mucosal adjuvants may play an important role in the future development of mucosal, non-living vaccine formulations. Here we will review some recent developments in enteric vaccine development with an emphasis on bacterial vaccines. Table 1 lists some of the main bacterial pathogens that cause enteric diseases in humans and provides examples of vaccines that have recently been licensed for human use or have been evaluated in the clinic. Many of the listed pathogens are members of the Enterobacteriacae including Escherichia coli, Shigellae and Salmonella enterica. Enteric infectionassociated diseases can be caused by live agents (such as bacterial dysentery), by the toxins they release (such as staphyloccocal food poisoning), or by a combination of these factors (such as cholera). Some of these pathogens act mainly through infections at the mucosal surfaces of the body (such as Vibrio cholerae) where as others are able to cause systemic infections (such as S. enterica subspecies enterica serovar Typhi or S. Typhi). Thus, the pathogenesis, aetiology and consequently immunity of these infections are diverse. One point to take from Table 1 is that vaccine development has been relatively slow in this area. This becomes more obvious when vaccine efficacy and uptake is taken into consideration. Many of the early vaccines, such as the whole cell, inactivated cholera vaccine were of low efficacy (often inducing less than a 50% chance of protection). The injected vaccines were also often significantly reactogenic and required multiple and regular doses. Consequently, vaccine compliance was poor. Mainly as a consequence of these factors, none of these vaccines are currently commonly used in children's vaccination programmes or EPI (Extended Programme of Immunisation) run through the World Health Organization. This means that most enteric vaccines are used sporadically, either to protect travellers or individual groups at severe risk.
Early vaccine development
A further complicating factor for enteric vaccine development is economic. Many potential vaccinees are located in the poorer nations and consequently cannot afford to buy vaccines. In addition, even in Despite these problems, in recent years efforts to develop enteric vaccines have been intense. The field has been significantly stimulated by our improved understanding of the molecular basis of enteric infections. We now understand much more about how these infections are established and how the immune system controls them. We have been able to identify novel candidate vaccine antigens, develop candidate attenuated strains for live vaccines, and produce better systems for delivery and enhancing the immunogenicity of vaccines against enteric pathogens. To consider recent enteric vaccine development in a logical way, it is worth discussing the development of live vaccines separately from non-living vaccines.
Recent advances in live enteric vaccine development
Many investigators have favoured the use of live vaccines to tackle enteric infections. This approach is driven by several factors including the generally poor immunogenicity of dead antigen preparations. Live enteric vaccines usually involve oral formulations and these are increasingly attractive for use in non-industrialised countries where needle contamination with disease agents such as hepatitis B and HIV is common (see http://www.vaccinealliance.org). Historically, our ability to develop live vaccine candidates was limited by the availability of safe, attenuated, bacterial strains that could form the basis of such vaccines. The isolation of attenuated strains used to rely on empirical approaches involving spontaneous or chemically induced mutation accumulation in individual bacterial isolates. Examples of such candidates included S. Typhi strain Ty21a 4 and V. cholerae strain Texas Star 5 . Both these strains were generated by chemical mutagenesis of the bacteria involving the induction of multiple undefined mutations in the genome. Although rigorous safety testing established that the vaccines did not readily revert to virulence, they suffered the disadvantage that they were difficult to quality control, as the stability of individual mutations could not easily be monitored. Nevertheless, Ty21a was successfully developed as a human oral typhoid vaccine and is now licensed in many countries. Both vaccines were initially tested for safety and immunogenicity in volunteers. V. cholerae Texas Star, which harboured a mutation in the cholera enterotoxin genes, was found to be highly immunogenic but was not developed further 6 . Ty21a was thoroughly evaluated in volunteers and in successive field studies in different parts of the world using different formulations. This vaccine was consistently demonstrated to induce about 60% protection against typhoid if 3-4 doses of vaccine were employed [7] [8] [9] [10] [11] [12] .
The perceived limitations of the early vaccines has stimulated a scramble to produce live attenuated vaccine candidates harbouring fully defined attenuating mutations constructed using modern genetic manipulation techniques. The Holy Grail in this area is to develop a vaccine that can induce protection in a single dose while not inducing any significant clinical reaction in vaccinees. This has proved a difficult end-point to achieve. A number of clinical centres have been established around the world to test live vaccine candidates in controlled and contained clinical environments, and many vaccine candidates have now been administered to volunteers in such centres. Perhaps the most work has been undertaken on S. Typhi and Shigella with some significant work on V. cholerae.
Live typhoid vaccine development has focused on the generation of mutant S. Typhi harbouring two or more genetically defined and stable attenuating mutations. Several candidates have been shown to be relatively non-reactogenic and significantly immunogenic 13, 14 . Perhaps the most extensively characterised S. Typhi harbours mutations in aroC and aroD (effecting metabolism of the aromatic ring and effectively starving the bacteria in the host) and htrA (encoding a protein involved in macrophage survival) 14 . This strain, known as CVD908 HtrA, has been used in volunteers both as a typhoid vaccine candidate and also as a vector for delivering antigens from other pathogens (such as Plasmodium or hepatitis B) to the mucosal immune system 15, 16 . Oral administration of a single dose induces significant anti-S. Typhi mucosal and systemic humoral and cellular immunity 14 .
Many research groups have attempted to develop genetically defined live
Shigella vaccines suitable for use to induce oral protection against dysentery. Many have achieved the goal of generating immunogenic vaccines that show great promise, but a consistent problem with live Shigella vaccine development has been reactogenicity 17, 18 . Shigellosis is normally a highly invasive disease that induces considerable immune pathology in the intestine. The ability of vaccines to invade may be a prerequisite for the induction of effective immunity and striking the balance between immunogenicity and reactogenicity will determine the fate of any candidate live Shigella vaccines. Nevertheless, some candidates are showing great promise, particularly one developed in China.
Attempts to develop live oral cholera vaccines have focused on the generation of V. cholerae mutants harbouring defined mutations in the cholera enterotoxin genes. Enterotoxin mutations are often combined with other mutations that either further attenuate the strain or act as genetic markers for monitoring shedding. The early volunteer studies using enterotoxin mutant V. cholerae were very encouraging 19 . Volunteers tolerated oral doses of the live vaccine well, and the strains were highly immunogenic in terms of their ability to induce local and system vibriocidal antibodies. These early successes encouraged field efficacy studies with the candidate, but a major study in Indonesia provided little evidence for the induction of protective immunity against cholera 20 . One major factor highlighted during these trials was that significantly higher doses of vaccine were needed in individuals in nonindustrialised countries to induce similar levels of immunity to those observed in western volunteers. This has been attributed, in part, to physiological and architectural differences between the bowel walls of individuals from the two areas. These differences may be a consequence of the diet or type of antigens encountered in the different environment that consequently stimulate different gut development patterns. This difference is now perceived as a real barrier to oral vaccine development and merits more detailed investigation.
Few other attempts to generate live attenuated pathogens made with other enteric bacteria have reached the volunteer stage. Work on E. coli has been hampered by the multitude of serologically distinct E. coli strains and the perceived need to develop multivalent vaccines. Several volunteer studies have been performed to assess the role of different putative virulence factors in enteropathogenic E. coli, but these so far have not been followed up with detailed safety/immunogenicity studies 21, 22 . Work on non-typhoidal S. enterica has been limited by the perceived lack of a market for such vaccines in humans and work on Campylobacter has been limited by the lack of candidate vaccines.
Another alternative approach to live enteric vaccine development would be to use genetic manipulation to construct vector strains expressing heterologous antigens from other enteric pathogens. This has been investigated at an experimental level using vectors as carriers for fimbrial or toxin-based antigens, but, although it is an attractive idea, progress has been slow [23] [24] [25] .
Non-living oral vaccines
Historically, few non-living vaccines have been developed that can routinely be administered via the oral route. This is because of the poor mucosal immunogenicity of most non-living antigens, combined with the lack of effective mucosal adjuvants and delivery systems. Volunteers have been fed a number of antigens, such as fimbriae/pili, but generally immunogenicity has either been poor or inconsistent. This is in spite of the fact that hundreds of papers are published each year showing effective oral immunisation in model systems. A few observations have been made that might be used to improve this field in the future. Antigens that actively bind mucosal or immune cells and/or are able to resist degradation by gut enzymes often have enhanced mucosal immunogenicity. Encapsulation of antigen into materials that offer such protection (and also form particles) can also enhance mucosal immunogenicity 26 . Finally, some molecules (e.g. cholera toxin) have been shown to have mucosal adjuvanting properties, activating immune responses to mucosally co-administered antigens 27, 28 . At the moment, cholera toxin is regarded as being too toxic for oral use as an adjuvant in humans, although non-toxic mutant derivatives of cholera toxin and the related E. coli heat-labile toxin are under evaluation 29 . Oral vaccination with non-living antigens is a field in desperate need of a significant breakthrough in human studies. In spite of these problems, some slow but significant progress has been made. An oral cholera vaccine has been developed based on chemically inactivated whole V. cholerae cells supplemented with the B subunit protein of cholera toxin 30 . This vaccine has been shown to induce some protection against cholera in field studies in Bangladesh. Indeed, this vaccine also offers some short-term protection against E. coli. The vaccine design takes advantage of the cell binding activity of the B subunit and the particulate and stable nature of the inactivated whole V. cholerae cells. However, immunogenicity is still not optimal as the administration of several doses is required to induce moderate protection. A similar vaccine is now under development for use against E. coli 31 . This simple approach would appear to have a limited future.
A future breakthrough in this area will probably rely on a combination of technological developments. Cheap and effective mucosal adjuvants that can also improve the efficiency of antigen delivery to mucosal surfaces are urgently needed. One problem is that many mucosal vaccines that prove effective in small animals show poor immunogenicity in humans. Thus, the screening of molecules with mucosal potential is difficult without effective human immune correlates.
Non-living parenteral vaccines
Attempts to develop non-living parenteral vaccines against enteric bacteria have met with mixed success. Early work with inactivated whole bacterial cells ran into the problem of reactogenicity (due to lipopolysaccharide contamination) and poor efficacy. One solution is to move to more defined vaccine antigens. This presents the problem of identifying non-toxic protective antigens. Early work with inactivated parenteral cholera toxin proved ineffective, but work with acellular typhoid vaccines based on the Vi polysaccharide has proved more successful. Vi (virulence) polysaccharide is a capsular material produced by S. Typhi. It can be readily purified and is immunogenic in adults but not infants. Vi polysaccharide has been shown to be an effective single dose vaccine against typhoid, inducing up to 70% protection in some field studies 32 . Indeed, Vi-based vaccines have now replaced whole cell typhoid vaccines in many parts of the world. Work is now under way to generate a conjugated form of Vi vaccine that is immunogenic in children under 2 years of age. Studies in older children in Vietnam have shown considerable promise 33 . Further studies should be performed over the next few years.
Other enteric vaccines
This short review has not been comprehensive in coverage of vaccines that could be defined as enteric. Diseases such as botulism could be considered to be of enteric origin and vaccine development is active in this area. Also, vaccine research on Helicobacter pylori, a cause of gastritis, has been intensive with a number of recent volunteer studies. However, as H. pylori is mainly associated with colonisation of the stomach, it has not been considered here.
The gaps
Progress in this area of research has been slow but sure over the past 20 years. However, there is no room for complacency as we still have many areas of disease that have not been effectively covered. Indeed, most of the existing vaccines against enteric pathogens could be significantly improved. Both existing live and non-living (Vi) vaccines against typhoid are showing promise. There is probably a clinical need for both types of vaccine in different settings as the two have complementary routes of delivery and mechanisms of inducing protection. There is an interest in introducing typhoid vaccines into the EPI programme in certain countries, but this will have to wait until the appropriate vaccines are available. Shigella vaccines are still held up in the early phases of human testing except in China where much more extensive field work has been performed. Much of the focus has been on live vaccines, but recent work on lipopolysaccharide conjugate vaccines is showing promise. Efforts to develop a live cholera vaccine are still suffering the impact of the disappointing field results obtained in Indonesia. However, work on reformulation of this vaccine may provide a breakthrough. Efforts to develop an E. coli vaccine, particularly for use in travellers, are still compromised by the fact that multiple antigenic types are likely to be required to obtain proper vaccine coverage. More research in volunteers with experimental challenge systems could shed light in this area. Efforts to develop vaccines against other enteric bacteria such as non-typhoidal Salmonella and Campylobacter are more likely to be held up by economic considerations, as at present there is no obvious market or clear demand for such vaccines.
